Profil
Pawel Krysiak is currently the President & Chief Executive Officer at M6P Therapeutics.
Aktive Positionen von Pawel Krysiak
| Unternehmen | Position | Beginn |
|---|---|---|
M6P Therapeutics
 M6P Therapeutics BiotechnologyHealth Technology M6P Therapeutics is a biotechnology company that develops targeted recombinant enzyme and gene therapies for lysosomal storage disorders. M6P Therapeutics is based in St. Louis, MO and their mission is to translate advanced science into therapies that address unmet needs within the LSD community. The private company's proprietary bicistronic-s1s3 platform enhances phosphorylation of lysosomal enzymes for both recombinant enzyme and gene therapies, leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. The company was founded in 2017 by Cuong Viet Do, Stuart Kornfeld, Lin Liu, and the CEO is Pawel Krysiak. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
M6P Therapeutics
M6P Therapeutics BiotechnologyHealth Technology M6P Therapeutics is a biotechnology company that develops targeted recombinant enzyme and gene therapies for lysosomal storage disorders. M6P Therapeutics is based in St. Louis, MO and their mission is to translate advanced science into therapies that address unmet needs within the LSD community. The private company's proprietary bicistronic-s1s3 platform enhances phosphorylation of lysosomal enzymes for both recombinant enzyme and gene therapies, leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. The company was founded in 2017 by Cuong Viet Do, Stuart Kornfeld, Lin Liu, and the CEO is Pawel Krysiak. | Health Technology |